In late 2018, Cardiol Therapeutics (TSX: CRDL) (OTC: CRTPF) commenced trading on the Toronto Stock Exchange (TSX) and we have been closely following the Canadian biotech company.
We believe that the biotech industry will be one of the greatest beneficiaries of the legal cannabis movement and for this reason, investor should have Cardiol on their radar. During the last month, Cardiol has been under pressure and the shares have been coming off its 2019 highs. We believe that this decline has created a great opportunity for investors and wanted to highlighted the biotech cannabis company.
Focused on Developing Game-Changing Products
Cardiol represents an attractive growth opportunity and we are favorable on the system that they developed that encases lipophilic drugs, like CBD, in a hydrophilic shell. Cardiol’s platform allows for much higher levels of lipophilic active ingredients in the bloodstream and has the potential to deliver drugs to sites of disease in the body.
This represents a significant opportunity for the cannabis biotech company and we will watch how the team executes on this. There are a number of avenues for growth with this proprietary technology and we think that this is something that investors need to be watching.
If Cardiol wants to start licensing the technology, we believe there will be significant demand for it. If the company wants to sell the technology, we believe that it would fetch a high price. The company could also use this technology to partner with other businesses and we think this represents a significant opportunity.
Secures Strategic Relationships to Support Growth
One of the ways that Cardiol has been able to differentiate itself is through its exclusive global manufacturing agreement with Dalton Pharma Services, a Health Canada approved, FDA registered, cGMP manufacturer of pharmaceutical cannabinoids, for the supply of pharmaceutical CBD for commercial introduction.
In collaboration with its exclusive manufacturing partner Dalton Pharma Services, Cardiol produces pharmaceutical cannabidiol for its own research purposes, while preparing to commercialize cannabidiol products later this year.
Cardiol has done a fantastic job when it comes to creating strategic relationship and we are favorable on its exclusive supply agreement with Noramco for the manufacture and supply of pure pharmaceutical CBD in Canada and Mexico. Through this relationship, Cardiol will have access to enough capacity to scale the amount of pharmaceutical grade pure CBD that is being produced. Noramco is a global leader in the manufacturing and suppling of controlled drug substance APIs and we are bullish on the growth prospects associated with this relationship.
Working on Major Biotech Initiatives
Cardiol is working with the University of Alberta on a research program that is focused on the development of proprietary nanoformulations of anti-inflammatory and anti-fibrotic drugs designed to improve pharmacokinetics and target the disease area.
Cardio has been focused on advancing its portfolio of proprietary pharmaceutical formulations and we believe that this is something of significance. The portfolio formulation that we are most excited about is CTX01, which is its proprietary pharmaceutical CBD formulation that is meant for the treatment of heart failure.
Chronic heart failure affects more than six million people in Canada and the United States and is associated with obesity and diabetes. Cardio believes that the available evidence shows that CBD could be an effective treatment for heart failure and is working to establish a clinical trial program in the first half of 2019.
If you look at Cardiol’s Scientific Advisory Board, you will see that it is comprised of several well-known and highly respected individuals. We believe that this is an important aspect of the story when it comes to the development of pharmaceutical treatments and believe that it could be a major catalyst for the stock.
A Company with Catalysts for Growth
2018 was a banner year for Cardiol and we believe that 2019 will prove to be even more significant. The biotech cannabis company represents a differentiated opportunity that has major catalysts for growth and we believe that the shares have been flying under the radar.
In 2019, Cardiol plans to introduce to the market a Health Canada-certified pharmaceutical CBD product boasting greater than 99.5% purity and this represents a major opportunity for the business. The biotech cannabis company is also highly focused on advancing its clinical trial programs for heart disease and we are favorable on the growth prospects associated with these projects.
Cardiol recently commenced trading on the TSX and is starting to generate more awareness. You should be watching this company before the market becomes more aware of this opportunity and please reach out to firstname.lastname@example.org to receive updates on Cardiol.